Categories AlphaGraphs, Earnings, Industrials
Earnings: Uber Q3 loss narrows on strong revenue growth
Uber Technologies, Inc. (NYSE: UBER) on Tuesday reported a narrower net loss for the third quarter of 2022 when the ride-hailing company’s revenues increased by double digits amid strong booking growth.
Net loss for the September quarter was $1.21 billion or $0.61 per share, compared to a loss of $2.42 billion or $1.28 per share in the corresponding period of last year. The bottom line, meanwhile, fell short of expectations.
The improvement reflects a 72% increase in net revenues to $8.34 billion in the most recent quarter from $4.85 billion in the third quarter of 2021, with all three operating segments registering strong growth. Revenues also beat estimates. At $29.12 billion, gross bookings were higher by 26%, and up 32% on a constant-currency basis.
Check this space to read management/analysts’ comments on Uber’s Q3 2022 earnings
“Our global scale and unique platform advantages are working together to drive more profitable growth, with Gross Bookings growth of 32% and record Adjusted EBITDA of $516 million,” said Dara Khosrowshahi, chief executive officer of Uber.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent